Search

everythinglearnresearchcommunity

for

Search:↓

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

A user shared their positive experience with scalp micropigmentation (SMP) to cover hair thinning and a scar, choosing it over hair transplants due to its non-invasive nature and realistic results. They recommend SMP for those struggling with hair loss, emphasizing the importance of finding a trusted artist.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It suggests that affordable genetic therapy could be the ultimate solution.

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.

Minoxidil is extremely toxic to cats, even in small amounts, and can be fatal. Switching to oral minoxidil is safer for cat owners, but precautions should still be taken to prevent exposure.

Minoxidil is highly toxic to cats and can be fatal with minimal exposure. Users suggest switching to oral minoxidil or taking precautions to prevent pet exposure.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

The user has been using minoxidil, finasteride, and microneedling for two years, resulting in significant hair regrowth and plans for a 4000 graft hair transplant. The treatments have strengthened the donor area, making a hair transplant feasible.

The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.

The conversation discusses the potential of topical cetirizine (Zyrtec) for hair growth in comparison to minoxidil, noting cetirizine's ability to reduce prostaglandin D2, which inhibits hair growth. Users share mixed experiences with cetirizine for allergies and scalp health, and there's a mention of the risk of dementia with long-term antihistamine use.

Creating a propylene glycol-free Minoxidil and Tretinoin solution to reduce skin irritation and enhance effectiveness. An emulsifier like lecithin can help mix Tretinoin properly, and Minoxidil foam is an alternative without propylene glycol.

The conversation discusses using tretinoin as an additional treatment for hair loss alongside minoxidil, with plans to test its effectiveness by applying it to only one side of the scalp. The user intends to start this experiment after using minoxidil for a year.

The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.

A user offers an extra bottle of Koshine 0.5% solution for hair loss. The discussion involves interest in trying Pyrilutamide for hair treatment.

The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.

Bee venom at 0.001% concentration was more effective than 2% minoxidil in promoting hair growth in mice, possibly due to increased growth factors and reduced inflammation. Caution is advised due to potential allergic reactions and the reliance on animal data.

The user is seeking alternatives to Minoxidil due to heart issues and is considering microneedling with topical melatonin, copper peptides, resveratrol+fisetin, or stemoxydine, which reportedly have minimal side effects. They are asking for information on the effectiveness of these treatments.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

User asks where to purchase exosomes/AAPE for microneedling hair loss treatment. Links to research on hair regeneration therapy, stem cell therapy, exosome therapy, and dermal exosomes provided.

Shiseido's S-DSC hair regenerative treatment in Japan focuses on improving existing hair by thickening miniaturized follicles, not creating new ones. There is limited patient feedback and long-term data available.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.